This website uses cookies

We use cookies to personalize content and ads, to provide social media features and to analyze our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. We will only use cookies based on your decision.

Drug Testing and COVID-19

The hidden epidemic: drug overdoses rising during COVID-19

Data is revealing a troubling national trend in drug abuse

The COVID-19 pandemic has had far-reaching impacts on Americans’ health. The potentially deadly infections caused by the SARS-CoV-2 virus as well as the measures that society has taken to curb the spread have come with distinct challenges. Those suffering from opioid addiction are particularly at risk.

Opioid abuse and overdoses were already a critical nationwide crisis before the pandemic. Crucial resources and support systems for this highly vulnerable population are now facing service limitations and interrupted operations. Every minute counts when diagnosing and treating overdoses, and that has never been more true than now.

  • Social Isolation
  • Limited Access to Services
  • Changing Drug Supply Chains

Complete the form below to access the whitepaper "Evaluation of the ARK Fentanyl II Assay across Siemens Healthineers Platforms" and sign up for our email list around related topics.

To receive the document for free, please fill out the form below. In return, we will provide you the document and further marketing communication. The information you provide below will be processed as described further in the Privacy Notice.

*Required


Subscription Button Icon
Be the first to know about our events, training, and news